1-11 of 11
Ivana Gojo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure

Amer M. Zeidan, Hanna A. Knaus, Tara M. Robinson, Andrea M.H. Towlerton, Edus H. Warren, Joshua F. Zeidner, Amanda L. Blackford, Amy S. Duffield, David Rizzieri, Mark G. Frattini, Yair M. Levy, Mark A. Schroeder, Anna Ferguson, Katherine E. Sheldon, Amy E. DeZern, Ivana Gojo, Steven D. Gore, Howard Streicher, Leo Luznik, B. Douglas Smith
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (15): 3519–3527.
https://doi.org/10.1158/1078-0432.CCR-17-3763
Published: 31 July 2018
View article titled, A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure
Open the PDF for A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia

Keith W. Pratz, Michelle A. Rudek, Ivana Gojo, Mark R. Litzow, Michael A. McDevitt, Jiuping Ji, Larry M. Karnitz, James G. Herman, Robert J. Kinders, B. Douglas Smith, Steven D. Gore, Hetty E. Carraway, Margaret M. Showel, Douglas E. Gladstone, Mark J. Levis, Hua-Ling Tsai, Gary Rosner, Alice Chen, Scott H. Kaufmann, Judith E. Karp
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (4): 899–907.
https://doi.org/10.1158/1078-0432.CCR-16-1274
Published: 14 February 2017
View article titled, A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia
Open the PDF for A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia in another window
Includes: Supplementary data
Journal Articles

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia

Ivana Gojo, Jan H. Beumer, Keith W. Pratz, Michael A. McDevitt, Maria R. Baer, Amanda L. Blackford, B. Douglas Smith, Steven D. Gore, Hetty E. Carraway, Margaret M. Showel, Mark J. Levis, Amy E. Dezern, Douglas E. Gladstone, Jiuping Jay Ji, Lihua Wang, Robert J. Kinders, Marie Pouquet, Ismail Ali-Walbi, Michelle A. Rudek, Weijie Poh, James G. Herman, Larry M. Karnitz, Scott H. Kaufmann, Alice Chen, Judith E. Karp
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (3): 697–706.
https://doi.org/10.1158/1078-0432.CCR-16-0984
Published: 31 January 2017
View article titled, A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia
Open the PDF for A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

New Strategies in Acute Myelogenous Leukemia: Leukemogenesis and Personalized Medicine

Ivana Gojo, Judith E. Karp
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (24): 6233–6241.
https://doi.org/10.1158/1078-0432.CCR-14-0900
Published: 14 December 2014
View article titled, New Strategies in Acute Myelogenous Leukemia: Leukemogenesis and Personalized Medicine
Open the PDF for New Strategies in Acute Myelogenous Leukemia: Leukemogenesis and Personalized Medicine in another window
Journal Articles

Translational Phase I Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytarabine and Etoposide in Patients with Relapsed, Refractory, or High-Risk Acute Myeloid Leukemia

Ivana Gojo, Ming Tan, Hong-Bin Fang, Mariola Sadowska, Rena Lapidus, Maria R. Baer, France Carrier, Jan H. Beumer, Bean N. Anyang, Rakesh K. Srivastava, Igor Espinoza-Delgado, Douglas D. Ross
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (7): 1838–1851.
https://doi.org/10.1158/1078-0432.CCR-12-3165
Published: 02 April 2013
View article titled, Translational Phase I Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytarabine and Etoposide in Patients with Relapsed, Refractory, or High-Risk Acute Myeloid Leukemia
Open the PDF for Translational Phase I Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytarabine and Etoposide in Patients with Relapsed, Refractory, or High-Risk Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

Preclinical Studies of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytosine Arabinoside and Etoposide for Treatment of Acute Leukemias

Ken Shiozawa, Takeo Nakanishi, Ming Tan, Hong-Bin Fang, Wen-chyi Wang, Martin J. Edelman, David Carlton, Ivana Gojo, Edward A. Sausville, Douglas D. Ross
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (5): 1698–1707.
https://doi.org/10.1158/1078-0432.CCR-08-1587
Published: 27 February 2009
View article titled, Preclinical Studies of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytosine Arabinoside and Etoposide for Treatment of Acute Leukemias
Open the PDF for Preclinical Studies of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytosine Arabinoside and Etoposide for Treatment of Acute Leukemias in another window
Includes: Supplementary data
Journal Articles

Phase II Trial of Tipifarnib as Maintenance Therapy in First Complete Remission in Adults with Acute Myelogenous Leukemia and Poor-Risk Features

Judith E. Karp, B. Douglas Smith, Ivana Gojo, Jeffrey E. Lancet, Jacqueline Greer, Maureen Klein, Larry Morris, Mark J. Levis, Steven D. Gore, John J. Wright, Elizabeth Garrett-Mayer
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (10): 3077–3082.
https://doi.org/10.1158/1078-0432.CCR-07-4743
Published: 15 May 2008
View article titled, Phase II Trial of Tipifarnib as Maintenance Therapy in First Complete Remission in Adults with Acute Myelogenous Leukemia and Poor-Risk Features
Open the PDF for Phase II Trial of Tipifarnib as Maintenance Therapy in First Complete Remission in Adults with Acute Myelogenous Leukemia and Poor-Risk Features in another window
Journal Articles

Phase I and Pharmacokinetic Study of Flavopiridol followed by 1-β-d-Arabinofuranosylcytosine and Mitoxantrone in Relapsed and Refractory Adult Acute Leukemias

Judith E. Karp, Antonino Passaniti, Ivana Gojo, Scott Kaufmann, Keith Bible, Tushar S. Garimella, Jacqueline Greer, Janet Briel, B. Douglas Smith, Steven D. Gore, Michael L. Tidwell, Douglas D. Ross, John J. Wright, A. Dimitrios Colevas, Kenneth S. Bauer
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (23): 8403–8412.
https://doi.org/10.1158/1078-0432.CCR-05-1201
Published: 01 December 2005
View article titled, Phase I and Pharmacokinetic Study of Flavopiridol followed by 1-β-<sc>d</sc>-Arabinofuranosylcytosine and Mitoxantrone in Relapsed and Refractory Adult Acute Leukemias
Open the PDF for Phase I and Pharmacokinetic Study of Flavopiridol followed by 1-β-<sc>d</sc>-Arabinofuranosylcytosine and Mitoxantrone in Relapsed and Refractory Adult Acute Leukemias in another window
Journal Articles

Phase I and Pharmacologic Study of Infusional Topotecan and Carboplatin in Relapsed and Refractory Acute Leukemia

Scott H. Kaufmann, Judith E. Karp, Louis Letendre, Timothy J. Kottke, Stephanie Safgren, Jackie Greer, Ivana Gojo, Pamela Atherton, Phyllis A. Svingen, David A. Loegering, Mark R. Litzow, Jeff A. Sloan, Joel M. Reid, Matthew M. Ames, Alex A. Adjei, Charles Erlichman
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (18): 6641–6649.
https://doi.org/10.1158/1078-0432.CCR-05-0817
Published: 15 September 2005
View article titled, Phase I and Pharmacologic Study of Infusional Topotecan and Carboplatin in Relapsed and Refractory Acute Leukemia
Open the PDF for Phase I and Pharmacologic Study of Infusional Topotecan and Carboplatin in Relapsed and Refractory Acute Leukemia in another window
Journal Articles

Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias: Therapy with Sequential 1-β-d-Arabinofuranosylcytosine, Mitoxantrone, and Bevacizumab

Judith E. Karp, Ivana Gojo, Roberto Pili, Christopher D. Gocke, Jacqueline Greer, Chuanfa Guo, David Qian, Lawrence Morris, Michael Tidwell, Helen Chen, James Zwiebel
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (11): 3577–3585.
https://doi.org/10.1158/1078-0432.CCR-03-0627
Published: 01 June 2004
View article titled, Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias: <subtitle>Therapy with Sequential 1-β-<sc>d</sc>-Arabinofuranosylcytosine, Mitoxantrone, and Bevacizumab</subtitle>
Open the PDF for Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias: <subtitle>Therapy with Sequential 1-β-<sc>d</sc>-Arabinofuranosylcytosine, Mitoxantrone, and Bevacizumab</subtitle> in another window
Journal Articles

The Cyclin-dependent Kinase Inhibitor Flavopiridol Induces Apoptosis in Multiple Myeloma Cells through Transcriptional Repression and Down-Regulation of Mcl-1

Ivana Gojo, Bin Zhang, Robert G. Fenton
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (11): 3527–3538.
Published: 01 November 2002
View article titled, The Cyclin-dependent Kinase Inhibitor Flavopiridol Induces Apoptosis in Multiple Myeloma Cells through Transcriptional Repression and Down-Regulation of Mcl-1
Open the PDF for The Cyclin-dependent Kinase Inhibitor Flavopiridol Induces Apoptosis in Multiple Myeloma Cells through Transcriptional Repression and Down-Regulation of Mcl-1 in another window